Literature DB >> 74723

Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect?

V S Hubbard, G D Dunn, P A di Sant'Agnese.   

Abstract

The percentage fatty-acid composition of the various plasma-lipid fractions from cystic-fibrosis patients with and without pancreatic insufficiency, obligate heterozygotes, and normal subjects was determined. Only the cystic-fibrosis patients with pancreatic insufficiency had significantly abnormal fatty-acid composition. This general observation did not correlate with vitamin-E deficiency, age, sex, or severity of the disease. Thus the altered fatty-acid composition of the different plasma-lipid fractions appears to be a secondary consequence of the pancreatic insufficiency commonly associated with cystic fibrosis and not a direct metabolic defect related to the cystic-fibrosis gene itself.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 74723     DOI: 10.1016/s0140-6736(77)90359-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  What is the association of essential fatty acid status with cystic fibrosis?

Authors:  V S Hubbard
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

2.  Fatty acid pattern of platelet phospholipids in cystic fibrosis.

Authors:  V Rogiers; A Vercruysse; I Dab; R Crokaert; H L Vis
Journal:  Eur J Pediatr       Date:  1984-09       Impact factor: 3.183

3.  Absorption of safflower oil and structured lipid preparations in patients with cystic fibrosis.

Authors:  V S Hubbard; M C McKenna
Journal:  Lipids       Date:  1987-06       Impact factor: 1.880

4.  Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency.

Authors:  V Rogiers; A Vercruysse; I Dab; D Baran
Journal:  Eur J Pediatr       Date:  1983-10       Impact factor: 3.183

5.  Application of a new test for vitamin E deficiency to cystic fibrosis.

Authors:  H A Cynamon; J N Isenberg
Journal:  Eur J Pediatr       Date:  1987-09       Impact factor: 3.183

6.  Serum fatty acid profiles in cystic fibrosis patients and their parents.

Authors:  A B Christophe; W J Warwick; R T Holman
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

7.  Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis.

Authors:  P L Zentler-Munro; D R Fine; J C Batten; T C Northfield
Journal:  Gut       Date:  1985-09       Impact factor: 23.059

8.  A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA.

Authors:  M Rabie Al-Turkmani; Charlotte Andersson; Ragheed Alturkmani; Waddah Katrangi; Joanne E Cluette-Brown; Steven D Freedman; Michael Laposata
Journal:  J Lipid Res       Date:  2008-05-14       Impact factor: 5.922

9.  Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects.

Authors:  C A Youngberg; R R Berardi; W F Howatt; M L Hyneck; G L Amidon; J H Meyer; J B Dressman
Journal:  Dig Dis Sci       Date:  1987-05       Impact factor: 3.199

10.  Mechanisms of lipid malabsorption in Cystic Fibrosis: the impact of essential fatty acids deficiency.

Authors:  N Peretti; V Marcil; E Drouin; E Levy
Journal:  Nutr Metab (Lond)       Date:  2005-05-03       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.